---
title: "PHIHDL: NMR-Derived HDL Index Predicts Pulmonary Hemodynamics and Survival in PAH"
id: "medrxiv-4-phihdl-a-novel-hdl-index-predicting-baseline-pulmonary-hemodynamics-and-long"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-4-phihdl-a-novel-hdl-index-predicting-baseline-pulmonary-hemodynamics-and-long"
content_type: "clinical_feed_article"
specialty: "Pulmonology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PHIHDL: NMR-Derived HDL Index Predicts Pulmonary Hemodynamics and Survival in PAH
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-4-phihdl-a-novel-hdl-index-predicting-baseline-pulmonary-hemodynamics-and-long
- **Specialty:** [Pulmonology](https://medichelpline.com/clinical-feed/pulmonology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study retrospectively analyzed 100 patients with **pulmonary arterial hypertension (PAH)** from the prospective GRAPH-M registry with complete diagnostic workup including right heart catheterization and baseline serum samples. - Median survival in the cohort was 8.0 years; 46 of 100 patients died during follow-up. Baseline hemodynamics: mean pulmonary arterial pressure (mPAP) 41 ± 16 mmHg, pulmonary arterial wedge pressure (PAWP) 8.8 ± 3.2 mmHg, pulmonary vascular resistance (PVR) 8.0 ± 4.9 Wood units. - Nuclear magnetic resonance (**NMR**) spectroscopy–derived metabolites and lipoprotein parameters were assessed for association with pulmonary hemodynamics and prognosis. - A cluster of 12 **HDL**-related measures showed significant inverse associations with pulmonary hemodynamics. From these measures the authors derived PHIHDL, defined as the reversed scaled average of those HDL particle metrics. - PHIHDL correlated inversely with worse pulmonary hemodynamics and was associated with higher all-cause mortality. Adjusted for age and sex, PHIHDL had hazard ratio (HR) 2.96 (95% CI 1.52–5.70) for mortality. - The prognostic association of PHIHDL remained independent of established clinical risk scores COMPERA 2.0 and REVEAL Lite2. - The cohort characteristics: mean age 61 ± 15 years, female:male ratio 2.5, body mass index 26 ± 7 kg/m2; patients were treated at the PH clinic of LKH University Hospital, Medical University of Graz between 2011 and 2021. - Data and code availability are reported: datasets uploaded to Zenodo with DOI provided. Ethical approval and written informed consent were obtained (Ethics Committee Medical University of Graz: EK: 23-408 ex 10/11). - Competing interests for several authors are disclosed; multiple authors reported no conflicts. Funding sources included Austrian Science Fund, Austrian Research Promotion Agency, regional and European funds. - The authors conclude that PHIHDL, a pulmonary hemodynamics–based metabolomic score, provides independent prognostic information beyond established risk scores in PAH.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=QzxMcIq0RZdVtiIhnCHH05ub1POl82bK8fXmjj67SI8-1788362410.9786372-1.2.1.1-RF5GZd.ospjdeInmqTlEW5vYXjfJMBqpLiCEWHQZgBGf6sR.oeqQedene8BfDaxp) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # PHIHDL: A Novel HDL Index Predicting Baseline Pulmonary Hemodynamics and Long-Term Survival in PAH [ View ORCID Profile](http://orcid.org/0009-0002-1028-5444)Sebastian Pritz, [ View ORCID Profile](http://orcid.org/0000-0002-9505-6271)Natalie Bordag, [ View ORCID Profile](http://orcid.org/0000-0002-8863-0298)Vasile Foris, [ View ORCID Profile](http://orcid.org/0000-0002-6277-1463)Valentina Biasin, [ View ORCID Profile](http://orcid.org/0000-0001-6004-1945)Helga Billensteiner, [ View ORCID Profile](http://orcid.org/0000-0001-5537-506X)Hansjoerg Habisch, [ View ORCID Profile](http://orcid.org/0000-0002-9725-5231)Tobias Madl, [ View ORCID Profile](http://orcid.org/0000-0002-2422-5381)Gunther Marsche, [ View ORCID Profile](http://orcid.org/0000-0003-3825-8587)Chandran Nagaraj, Susanne Suessner, [ View ORCID Profile](http://orcid.org/0000-0003-3709-2183)Gabor Kovacs, [ View ORCID Profile](http://orcid.org/0000-0002-9797-2599)Gustavo Heresi, [ View ORCID Profile](http://orcid.org/0000-0001-6859-8828)Ulrich Bodenhofer, [ View ORCID Profile](http://orcid.org/0000-0002-2834-7466)Horst Olschewski, [ View ORCID Profile](http://orcid.org/0000-0002-8189-3634)Andrea Olschewski doi: https://doi.org/10.64898/2026.08.31.26361587 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Sebastian Pritz 1 School of Informatics, Communications, and Media, University of Applied Sciences Upper Austria, Hagenberg, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sebastian%2BPritz%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pritz%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASebastian%2BPritz%2B) * [ORCID record for Sebastian Pritz](http://orcid.org/0009-0002-1028-5444 "Open in new tab") Natalie Bordag 2 Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Natalie%2BBordag%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bordag%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANatalie%2BBordag%2B) * [ORCID record for Natalie Bordag](http://orcid.org/0000-0002-9505-6271 "Open in new tab") Vasile Foris 3 Division of Pulmonology, Department of Internal Medicine, Lung Research Cluster, Medical University of Graz, Graz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vasile%2BForis%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Foris%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVasile%2BForis%2B) * [ORCID record for Vasile Foris](http://orcid.org/0000-0002-8863-0298 "Open in new tab") Valentina Biasin 3 Division of Pulmonology, Department of Internal Medicine, Lung Research Cluster, Medical University of Graz, Graz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Valentina%2BBiasin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Biasin%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AValentina%2BBiasin%2B) * [ORCID record for Valentina Biasin](http://orcid.org/0000-0002-6277-1463 "Open in new tab") Helga Billensteiner 1 School of Informatics, Communications, and Media, University of Applied Sciences Upper Austria, Hagenberg, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Helga%2BBillensteiner%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Billensteiner%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHelga%2BBillensteiner%2B) * [ORCID record for Helga Billensteiner](http://orcid.org/0000-0001-6004-1945 "Open in new tab") Hansjoerg Habisch 4 Division of Medicinal Chemistry, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Lung Research Cluster, Medical University of Graz, Graz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hansjoerg%2BHabisch%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Habisch%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHansjoerg%2BHabisch%2B) * [ORCID record for Hansjoerg Habisch](http://orcid.org/0000-0001-5537-506X "Open in new tab") Tobias Madl 4 Division of Medicinal Chemistry, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Lung Research Cluster, Medical University of Graz, Graz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tobias%2BMadl%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Madl%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATobias%2BMadl%2B) * [ORCID record for Tobias Madl](http://orcid.org/0000-0002-9725-5231 "Open in new tab") Gunther Marsche 5 Division of Pharmacology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Lung Research Cluster, Medical University of Graz, Graz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Gunther%2BMarsche%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Marsche%20G&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGunther%2BMarsche%2B) * [ORCID record for Gunther Marsche](http://orcid.org/0000-0002-2422-5381 "Open in new tab") Chandran Nagaraj 3 Division of Pulmonology, Department of Internal Medicine, Lung Research Cluster, Medical University of Graz, Graz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Chandran%2BNagaraj%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nagaraj%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChandran%2BNagaraj%2B) * [ORCID record for Chandran Nagaraj](http://orcid.org/0000-0003-3825-8587 "Open in new tab") Susanne Suessner 6 Blutzentrale Linz, Austrian Red Cross, Linz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Susanne%2BSuessner%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Suessner%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASusanne%2BSuessner%2B) Gabor Kovacs 4 Division of Medicinal Chemistry, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Lung Research Cluster, Medical University of Graz, Graz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Gabor%2BKovacs%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kovacs%20G&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGabor%2BKovacs%2B) * [ORCID record for Gabor Kovacs](http://orcid.org/0000-0003-3709-2183 "Open in new tab") Gustavo Heresi 7 Division of Pulmonary Medicine, Cleveland Clinic, Ohio, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Gustavo%2BHeresi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Heresi%20G&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGustavo%2BHeresi%2B) * [ORCID record for Gustavo Heresi](http://orcid.org/0000-0002-9797-2599 "Open in new tab") Ulrich Bodenhofer 1 School of Informatics, Communications, and Media, University of Applied Sciences Upper Austria, Hagenberg, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ulrich%2BBodenhofer%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bodenhofer%20U&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AUlrich%2BBodenhofer%2B) * [ORCID record for Ulrich Bodenhofer](http://orcid.org/0000-0001-6859-8828 "Open in new tab") Horst Olschewski 8 Sigmund Freud Private University Vienna, Faculty of Medicine, Vienna, Austria * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Horst%2BOlschewski%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Olschewski%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHorst%2BOlschewski%2B) * [ORCID record for Horst Olschewski](http://orcid.org/0000-0002-2834-7466 "Open in new tab") * For correspondence: horst.olschewskigraz@gmail.com Andrea Olschewski 4 Division of Medicinal Chemistry, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Lung Research Cluster, Medical University of Graz, Graz, Austria; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andrea%2BOlschewski%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Olschewski%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAndrea%2BOlschewski%2B) * [ORCID record for Andrea Olschewski](http://orcid.org/0000-0002-8189-3634 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1290122/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1290122/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1290122/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1290122/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1290122/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Rationale: Pulmonary hypertension is defined by pulmonary hemodynamics, but diagnostic and prognostic biomarkers remain limited. Nuclear magnetic resonance (NMR) spectroscopy provides detailed insights, particularly in the lipid metabolism. Objectives: To explore circulating NMR-derived metabolites and lipoprotein-related parameters for their association with pulmonary hemodynamics and to analyse their prognostic properties in pulmonary arterial hypertension (PAH). Methods: Retrospective analysis of a PAH cohort with complete diagnostic workup including right heart catheterization and baseline serum samples, from the prospective GRaz Pulmonary Hypertension-Metabolism (GRAPH-M) registry. Measurements: NMR-derived metabolites and lipoprotein-related parameters were analyzed for their association with clinically relevant parameters of PAH. We defined PHIHDL, a score derived from high-density lipoprotein (HDL) related measures based on their strong association with pulmonary hemodynamics, and evaluated its prognostic value. Results: We included 100 patients with PAH treated at the PH clinic of LKH University Hospital, Medical University of Graz, between 2011 and 2021. Age was 61±15 years, female/male ratio 2.5, BMI 26 ±7 kg/m2, mPAP 41±16 mmHg, PAWP 8.8±3.2 mmHg, PVR 8.0±4.9 WU, and median survival was 8.0 years. During follow-up, 46 patients died. We identified a cluster of 12 HDL-related measures that showed significant inverse association to pulmonary hemodynamics and derived PHIHDL from the reversed scaled average of these particles. PHIHDL was associated with all-cause mortality after adjustment for age and sex (HR 2.96, 95% CI 1.52-5.70), independent of the clinical risk scores COMPERA 2.0 and REVEAL Lite2. Conclusion: PHIHDL, a pulmonary hemodynamics-based metabolomic score, provides independent prognostic information beyond established risk scores in PAH. ### Competing Interest Statement VF received honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Janssen, Chiesi, BMS, and Boehringer Ingelheim and support for attending meetings, and/or travel from Janssen, MSD, and Boehringer Ingelheim outside the submitted work. VF was supported by a Mid-Term Career Fellowship of the Austrian Society of Pneumology, Max Kade Fellowship and TOPMed Fellowship. AO received honoraria for presentations and support for attending meetings, and/or travel from MSD outside the submitted work. HO reports personal fees and non-financial support from Astra Zeneca, Bayer, Inhibikase, IQVIA, Janssen, Liquidia, Pulmovant, Menarini, MSD, and Paul, Weiss, outside the submitted work. GK declares payments for non-branded non-promotional Speakers Bureaus from Bayer Healthcare and Merck, for Steering Committee Membership for a clinical trial from Johnson & Johnson, for Advisory Boards from Merck and United Therapeutics. SP, HB, UB, NB declare no conflict of interest, financial or otherwise. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All subjects provided written informed consent, and the study protocol was approved by the Ethics Committee of the Medical University of Graz (EK: 23-408 ex 10/11). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced are available online at https://doi.org/10.5281/zenodo.21991904 ## Funder Information Declared FWF Austrian Science Fund, https://ror.org/013tf3c58, 10.55776/COE14, 10.55776/P28854, 10.55776/I3792, 10.55776/DOC130, 10.55776/W1226 Austrian Research Promotion Agency, https://ror.org/028jc0449, 864690, 870454 Amt der Steiermärkischen Landesregierung, https://ror.org/00jg7hp37 City of Graz Austrian Research Promotion Agency, https://ror.org/028jc0449, 912192 European Regional Development Fund, 912192 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.28.26361585v1 "Default-filled outcome labels in a deployed cognitive-screening programme: an operator-level audit and the construction of twenty-four language-model arms")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.31.26361841v1 "Sensorimotor effects of heatwrap and exercise in acute low back pain: results of a randomised controlled trial") Posted September 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.31.26361587v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/02/2026.08.31.26361587.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOp
## Related Clinical Research

- [Triglyceride-Glucose (TyG) Index and Mortality in Non-Diabetic Fibrotic Lung Disease on Antifibrot](https://medichelpline.com/clinical-feed/plos-one-1-association-between-triglyceride-glucose-index-and-all-cause-mortality-in-non.md)
- [Connexin 43 in Hyperoxia-Induced Bronchopulmonary Dysplasia and Associated Pulmonary Hypertension](https://medichelpline.com/clinical-feed/plos-one-19-role-of-connexin-43-in-hyperoxia-induced-bronchopulmonary-dysplasia-and.md)
- [AI-driven Test-free Claims Model Predicts Trajectory Events in Fibrotic Interstitial Lung Disease](https://medichelpline.com/clinical-feed/medrxiv-5-natural-history-of-fibrotic-interstitial-lung-disease-using-ai-driven-test-free.md)
- [North West London Diabetes Cohort: multiethnic EHR resource for diabetes complications research](https://medichelpline.com/clinical-feed/bmj-open-2-large-scale-multiethnic-electronic-health-record-resource-for-diabetes.md)
- [Intensive blood pressure control linked to 15% lower 7-year dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-intensive-blood-pressure-control-cuts-7-year-dementia-risk-by-15-study-finds.md)

## Navigation
- [← Back to Pulmonology Feed](https://medichelpline.com/clinical-feed/pulmonology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.